[en] BACKGROUND: Activation and coagulation biomarkers were measured within the Strategies for Management of Antiretroviral Therapy (SMART) trial. Their associations with opportunistic disease (OD) in human immunodeficiency virus (HIV)-positive patients were examined. METHODS: Inflammatory (high-sensitivity C-reactive protein [hsCRP], interleukin-6 [IL-6], amyloid-A, and amyloid-P) and coagulation (D-dimer and prothrombin-fragment 1+2) markers were determined. Conditional logistic regression analyses were used to assess associations between these biomarkers and risk of OD. RESULTS: The 91 patients who developed an OD were matched to 182 control subjects. Patients with an hsCRP level > or =5 microg/mL at baseline had a 3.5 higher odds of OD (95% confidence interval [CI], 1.5-8.1) than did those with an hsCRP level <1 microg/mL (P=.003, by test for trend) and patients with an IL-6 level > or =3 pg/mL at baseline had a 2.4 higher odds of OD (95% CI, 1.0-5.4) than did those with an IL-6 level <1.5 pg/mL (P=.02, by test for trend). No other baseline biomarkers predicted development of an OD. Latest follow-up hsCRP level for those with an hsCRP level > or =5 microg/mL (compared with a level <1 microg/mL; odds ratio [OR], 7.6; 95% CI, 2.0-28.5; [P=.002, by test for trend), latest amyloid-A level for those with an amyloid-A level > or =6 mg/L (compared with a level <2 mg/L; OR, 3.8; 95% CI, 1.1-13.4; P=.03, by test for trend), and latest IL-6 level for those with an IL-6 level > or =3 pg/mL (compared with a level <1.5 pg/mL; OR 2.4; 95% CI, 0.7-8.8; P=.04, by test for trend) were also associated with development of an OD. CONCLUSIONS: Higher IL-6 and hsCRP levels independently predicted development of OD. These biomarkers could provide additional prognostic information for predicting the risk of OD.
Disciplines :
Immunology & infectious disease
Author, co-author :
Rodger, Alison J
Fox, Zoe
Lundgren, Jens D
Kuller, Lewis H
Boesecke, Christoph
Gey, Daniela
Skoutelis, Athanassios
Goetz, Matthew Bidwell
Phillips, Andrew N
Other collaborator :
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén.
Language :
English
Title :
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
Publication date :
2009
Journal title :
Journal of Infectious Diseases
ISSN :
0022-1899
eISSN :
1537-6613
Publisher :
University of Chicago Press, Chicago, United States - Illinois
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count guided interruptions of antiretroviral therapy. N Engl J Med 2006;355:2283-2296
Kuller LH, Tracey R, Belloso W, et al. Activation of inflammatory and coagulation pathways is associated with mortality in patients with HIV infection. PLoS Med 2008;5(10):e203.
Hodge DR Peng B, Cherry J, et al. Interleukin 6 supports the maintenance of p53 tumour suppressor gene promotor methylation. Cancer Res 2005;65(11):4673-4682 (Pubitemid 40740803)
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836-843 (Pubitemid 30165206)
Honda H, Qureshi AR Heimbürger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47(1): 139-148 (Pubitemid 41828276)
Fahey JL. Prognostic significance of plasma markers of immune activation. AIDS 1998; 12:1581-1590
Osmond DH, Shiboski S, Bacchetti P, et al. Immune activation markers and AIDS prognosis. AIDS 1991;5:505-511
Aziz N, Parunag P, Taylor J, et al. Stability of plasma levels of cytokines and soluble activation markers in patients with HIV infection. J Infect Dis 1999; 179:843-848 (Pubitemid 29159329)
Lau B, Sharrett AR, Kingsley LA, et al. CRP is a marker for HIV disease progression. Arch Intern Med 2006; 166:64-70.
Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009; 66:9-26. Available at http://www.springerlink.com/content/n1w7n5016n3j1n76/. Accessed 23 August 2008.
Lifson AR, Belloso WH, Carey C, et al. Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials 2008;9(3):177-185 (Pubitemid 351892871)
Lundgren JD, Babiker A, El-Sadr W, et al. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV-RNA levels during follow-up. J Infect Dis 2008; 197(8):1145-1155
Petruckevitch A, Del Amo J, Phillips AN, et al. Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London. AIDS 1998; 12(9):1007-1013 (Pubitemid 28276967)
Lederman MM, Kalish LA, Asmuth D, Fiebig E, Mileno M, Busch MP. 'Modelling' relationships among HIV-1 replication, immune activation and CD4 T cell losses using adjusted correlative analyses. AIDS 2000; 14: 951-958
Sodora DL, Silvestři G. Immune activation and AIDS pathogenesis. AIDS 2008; 22(4):439-446
Giorgi JV, Lyles RH, Matud JL, et al. Multicenter AIDS Cohort Study. Predictive value of immunologic and virologie markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29(4):346-355
Wolf K, Tsakiris DA, Weber R Erb P, Battegay M; Swiss HIV Cohort Study. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with HIV J Infect Dis 2002; 185:456-462
Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ, Huang HF. IL-6 signaling by STAT3 participates in the change from hyperplasie to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 2001; 1:19. (Pubitemid 38846500)
Barillari G, Buonaguro L, Fiorelli V, et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992;149(11):3727-3734
Saldago R Benoy I, Weytjens R, et al. Arteriovenous gradients of ILK-6 and serum VEGF and D-Dimers in human cancer. Br J Cancer 2002; 87:1437-1444 (Pubitemid 36044320)
Bermudez LE, Wu M, Petrofsky M, Young LS. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun 1992; 60(10):4245-4252
Nordoy I, Muller F, Nordal KP, et al. The role of the tumour necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 2000; 181:51-57 (Pubitemid 30049032)
Drain PK, Kupka R, Msamanga GI, Urassa W, Mugusi F, Fawzi WW. C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS 2007; 21(15):2067-2075 (Pubitemid 47462156)
Phillips A; CASCADE Collaboration. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18(1):51-58